Patents by Inventor Darryl Kato

Darryl Kato has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR TREATING VIRAL INFECTIONS
    Publication number: 20260199380
    Abstract: This disclosure provides methods of treating HIV infections using Compound 1, or a pharmaceutically acceptable salt thereof, and a compound of Formula I, or a pharmaceutically acceptable salt thereof. The present disclosure further provides pharmaceutical formulations, comprising Compound 1, or a pharmaceutically acceptable salt thereof, and a compound of Formula I, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 8, 2025
    Publication date: July 16, 2026
    Inventors: Ana Z. Gonzalez Buenrostro, Darryl Kato, Gregg M. Schwarzwalder, Murali Subramanian
  • KRAS MODULATING COMPOUNDS
    Publication number: 20260167650
    Abstract: Provided herein are compounds, and pharmaceutically acceptable salts thereof, useful as KRAS inhibitors and/or degraders, methods of making and using the same (singly or in combination with additional agents), and pharmaceutical compositions thereof.
    Type: Application
    Filed: October 9, 2025
    Publication date: June 18, 2026
    Inventors: Eda Y. Canales, Zhimin Du, Yassin M.A. Elbatrawi, Quinn B. Greven, Tezcan Guney, Darryl Kato, Henok H. Kinfe, Scott E. Lazerwith, Christopher J. Swank, Rhiannon Thomas-Tran, Guanghu Tong, William J. Watkins
  • HIV INHIBITOR COMPOUNDS
    Publication number: 20260132139
    Abstract: The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herin. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I.
    Type: Application
    Filed: October 22, 2025
    Publication date: May 14, 2026
    Inventors: Elizabeth M. Bacon, Elbert Chin, Jeromy J. Cottell, Ashley Anne Katana, Darryl Kato, John O. Link, Nathan Shapiro, Teresa Alejandra Treo Martin, Zheng-Yu Yang
  • KRAS G12D MODULATING COMPOUNDS
    Publication number: 20260116882
    Abstract: Provided herein are compounds, and pharmaceutically acceptable salts thereof, useful as KRAS G12D and/or KRAS G12C inhibitors, methods of making and using the same (singly or in combination with additional agents), and pharmaceutical compositions thereof.
    Type: Application
    Filed: September 26, 2025
    Publication date: April 30, 2026
    Inventors: Chaodi Dai, Hongyan Guo, Darryl Kato, Scott E. Lazerwith, Jonathan William Medley, Thomas C.J. Mies, Hyung-Jung Pyun, William J. Watkins, Jennifer R. Zhang
  • KRAS MODULATING COMPOUNDS
    Publication number: 20260098049
    Abstract: Provided herein are compounds, and pharmaceutically acceptable salts thereof, useful as KRAS inhibitors, methods of making and using the same (singly or in combination with additional agents), and pharmaceutical compositions thereof.
    Type: Application
    Filed: August 11, 2025
    Publication date: April 9, 2026
    Inventors: Eda Y. Canales, Christopher T. Clark, Zhimin Du, Yassin M.A. Elbatrawi, Quinn B. Greven, Tezcan Guney, Darryl Kato, Henok H. Kinfe, Irene N. Kiburu, Scott E. Lazerwith, Thomas C.J. Mies, Christopher J. Swank, Rhiannon Thomas-Tran, Guanghu Tong, William J. Watkins, Wilian Augusto Cortopassi Coelho
  • THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION
    Publication number: 20260035357
    Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of a Retroviridae infection, including an HIV infection.
    Type: Application
    Filed: July 7, 2025
    Publication date: February 5, 2026
    Inventors: Gediminas J. Brizgys, Chienhung Chou, Hang Chu, Julie Farand, Michael Graupe, Tezcan Guney, Darryl Kato, Jiayao Li, John O. Link, James B. C. Mack, Dong Min Mun, Scott D. Schroeder, William J. Watkins, Qiaoyin Wu, Jennifer R. Zhang
  • HIV inhibitor compounds
    Patent number: 12479853
    Abstract: The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I.
    Type: Grant
    Filed: June 27, 2024
    Date of Patent: November 25, 2025
    Assignee: Gilead Sciences, Inc.
    Inventors: Elizabeth M. Bacon, Elbert Chin, Jeromy J. Cottell, Ashley Anne Katana, Darryl Kato, John O. Link, Nathan Shapiro, Teresa Alejandra Trejo Martin, Zheng-Yu Yang
  • KRAS G12D modulating compounds
    Patent number: 12448400
    Abstract: Provided herein are compounds, and pharmaceutically acceptable salts thereof, useful as KRAS G12D and/or KRAS G12C inhibitors, methods of making and using the same (singly or in combination with additional agents), and pharmaceutical compositions thereof.
    Type: Grant
    Filed: December 23, 2024
    Date of Patent: October 21, 2025
    Assignee: Gilead Sciences, Inc.
    Inventors: Chaodi Dai, Juan A. Guerrero, Darryl Kato, Scott E. Lazerwith, Jonathan William Medley, Thomas C. J. Mies, Hyung-Jung Pyun, Hayato Shiotsu, Maoqun Tian, William J. Watkins, Jennifer R. Zhang
  • Therapeutic compounds for HIV virus infection
    Patent number: 12404262
    Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of a Retroviridae infection, including an HIV infection.
    Type: Grant
    Filed: December 2, 2022
    Date of Patent: September 2, 2025
    Assignee: Gilead Sciences, Inc.
    Inventors: Gediminas J. Brizgys, Chienhung Chou, Hang Chu, Julie Farand, Michael Graupe, Tezcan Guney, Darryl Kato, Jiayao Li, John O. Link, James B. C. Mack, Dong Min Mun, Scott D. Schroeder, William J. Watkins, Qiaoyin Wu, Jennifer R. Zhang
  • MCL1 INHIBITORS
    Publication number: 20250197421
    Abstract: The present disclosure generally relates to compounds of Formula (I) and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Application
    Filed: November 6, 2024
    Publication date: June 19, 2025
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, David W. Lin, Jonathan William Medley, Devan Naduthambi, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang, QingMing Zhu
  • THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION
    Publication number: 20250179102
    Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of a Retroviridae infection, including an HIV infection.
    Type: Application
    Filed: October 21, 2024
    Publication date: June 5, 2025
    Inventors: Julie Farand, Michael Graupe, Tezcan Guney, Darryl Kato, Jiayao Li, John O. Link, James B. C. Mack, Dong Min Mun, Roland D. Saito, William J. Watkins, Jennifer R. Zhang
  • MCL-1 INHIBITORS
    Publication number: 20250154116
    Abstract: The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Application
    Filed: October 17, 2024
    Publication date: May 15, 2025
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Tae H. Hwang, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, John E. Knox, Scott E. Lazerwith, Xiaofen Li, David W. Lin, Jonathan W. Medley, Michael L. Mitchell, Devan Naduthambi, Zachary Newby, Neil H. Squires, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang
  • KRAS G12D MODULATING COMPOUNDS
    Publication number: 20250136621
    Abstract: Provided herein are compounds, and pharmaceutically acceptable salts thereof, useful as KRAS G12D and/or KRAS G12C inhibitors, methods of making and using the same (singly or in combination with additional agents), and pharmaceutical compositions thereof.
    Type: Application
    Filed: December 23, 2024
    Publication date: May 1, 2025
    Inventors: Chaodi Dai, Juan A. Guerrero, Darryl Kato, Scott E. Lazerwith, Jonathan William Medley, Thomas C.J. Mies, Hyung-Jung Pyun, Hayato Shiotsu, Maoqun Tian, William J. Watkins, Jennifer R. Zhang
  • KRAS G12D MODULATING COMPOUNDS
    Publication number: 20250109147
    Abstract: Provided herein are compounds, and pharmaceutically acceptable salts thereof, useful as KRAS G12D and/or KRAS G12C inhibitors, methods of making and using the same (singly or in combination with additional agents), and pharmaceutical compositions thereof.
    Type: Application
    Filed: September 6, 2024
    Publication date: April 3, 2025
    Inventors: Chaodi Dai, Juan A. Guerrero, Darryl Kato, Scott E. Lazerwith, Jonathan William Medley, Thomas C.J. Mies, Hyung-Jung Pyun, Hayato Shiotsu, Maoqun Tian, William J. Watkins, Jennifer R. Zhang
  • KRAS G12D MODULATING COMPOUNDS
    Publication number: 20250101042
    Abstract: Provided herein are compounds, and pharmaceutically acceptable salts thereof, useful as KRAS G12D and/or KRAS G12C inhibitors, methods of making and using the same (singly or in combination with additional agents), and pharmaceutical compositions thereof.
    Type: Application
    Filed: September 5, 2024
    Publication date: March 27, 2025
    Inventors: Wilian Augusto Cortopassi Coelho, Chaodi Dai, Juan A. Guerrero, Hongyan Guo, Darryl Kato, Scott E. Lazerwith, Jonathan William Medley, Hyung-Jung Pyun, Maoqun Tian, William J. Watkins, Jennifer R. Zhang
  • KRAS MODULATING COMPOUNDS
    Publication number: 20250059208
    Abstract: Provided herein are compounds, and pharmaceutically acceptable salts thereof, useful as KRAS inhibitors, methods of making and using the same (singly or in combination with additional agents), and pharmaceutical compositions thereof.
    Type: Application
    Filed: June 27, 2024
    Publication date: February 20, 2025
    Inventors: Wilian Augusto Cortopassi Coelho, Julie Farand, Michael Graupe, Juan A. Guerrero, Darryl Kato, Irene N. Kiburu, James B.C. Mack, Joshua L. Martin, Erik P. McAuley, Jonathan William Medley, Vickie H. Tsui, William J. Watkins
  • THERAPEUTIC COMPOUNDS FOR HIV
    Publication number: 20250042926
    Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of a Retroviridae infection, including an HIV infection.
    Type: Application
    Filed: May 30, 2024
    Publication date: February 6, 2025
    Inventors: Julie Farand, Darryl Kato, James B.C. Mack
  • HIV INHIBITOR COMPOUNDS
    Publication number: 20250042910
    Abstract: The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I.
    Type: Application
    Filed: June 27, 2024
    Publication date: February 6, 2025
    Inventors: Elizabeth M. Bacon, Elbert Chin, Jeromy J. Cottell, Ashley Anne Katana, Darryl Kato, John O. Link, Nathan Shapiro, Teresa Alejandra Trejo Martin, Zheng-Yu Yang
  • KRAS MODULATING COMPOUNDS
    Publication number: 20250042922
    Abstract: Provided herein are compounds, and pharmaceutically acceptable salts thereof, useful as KRAS inhibitors, methods of making and using the same (singly or in combination with additional agents), and pharmaceutical compositions thereof.
    Type: Application
    Filed: June 27, 2024
    Publication date: February 6, 2025
    Inventors: Chaodi Dai, Julie Farand, Juan A. Guerrero, Tezcan Guney, Hongyan Guo, Jason R. Hudlicky, Darryl Kato, Irene N. Kiburu, Scott E. Lazerwith, Paulo A. Machicao Tello, James B.C. Mack, Erik P. McAuley, Jessica L. McKinley, Jonathan William Medley, Hyung-Jung Pyun, Thomas P. Stratton, Maoqun Tian, Jeremy R. Tuck, William J. Watkins, Jie Xu, Jennifer R. Zhang
  • MCL1 inhibitors
    Patent number: 12202842
    Abstract: The present disclosure generally relates to compounds of Formula (1) and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Grant
    Filed: March 9, 2023
    Date of Patent: January 21, 2025
    Assignee: Gilead Sciences, Inc.
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, David W. Lin, Jonathan William Medley, Devan Naduthambi, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang, Qingming Zhu